Breaking News Instant updates and real-time market news.

Mednax approached by potential PE bidders, Reuters says

06

Dec

MDMednax

$48.18

-1.61 (-3.23%)

09/17/17

KEYB

09/17/17UPGRADETarget $51KEYBOverweight

MEDNAX upgraded to Overweight from Sector Weight at KeyBanc

KeyBanc analyst Jason Gurda upgraded MEDNAX to Overweight with a $51 price target. Gurda expects a moderation in operating headwinds over the next few quarters, cost cutting/new revenue to offset some of the headwinds, thinks the radiology business is poised for strong growth, and views the company as a potential acquisition target over the next few years.

09/18/17

KEYB

09/18/17UPGRADETarget $51KEYBOverweight

Mednax upgraded to Overweight from Sector Weight at KeyBanc

KeyBanc analyst Jason Gurda upgraded Mednax to Overweight with a $51 price target. The analyst sees the company's operating headwinds moderating over the next few quarters and growth in its third specialty, radiology, accelerating in the the near-term. He thinks the shares at current levels are "relatively inexpensive."

09/18/17

09/18/17UPGRADE

On The Fly: Top five analyst upgrades

Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Caterpillar (CAT) upgraded to Buy from Neutral at UBS with analyst Steven Fisher saying his firm's latest analysis of private non-residential construction ex-Power shows a re-acceleration in activity in the fourth quarter and mid-single digit growth into 2018. 2. Mednax (MD) upgraded to Overweight from Sector Weight at KeyBanc analyst Jason Gurda saying he sees the company's operating headwinds moderating over the next few quarters and growth in its third specialty, radiology, accelerating in the the near-term. 3. Infosys (INFY) upgraded to Neutral from Sell at Goldman Sachs with the firm saying management uncertainty and guidance risk is already priced in. 4. Klondex Mines (KLDX) upgraded to Buy from Hold at Canaccord. 5. BP (BP) upgraded to Outperform from Market Perform at BMO Capital with analyst Brendan Warn saying he thinks the company's free cash flow will be boosted by "delivery of new upstream volumes, premium downstream product demand and improving (refining marker margin)." This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

10/16/17

BMOC

10/16/17INITIATIONTarget $46BMOCMarket Perform

Mednax initiated with a Market Perform at BMO Capital

BMO Capital analyst Matt Borsch initiated Mednax with an Market Perform and $46 price target due to unfavorable macroeconomic factors coupled with a slower-paced acquisition pipeline could lead to additional near-term volatility in financial results.

AT&T Mobility has reached a tentative agreement with the Communications Workers of America in Mobility Orange contract negotiations. The four-year agreement, which will be submitted to the union's membership for a ratification vote in coming days, covers about 20,000 employees in 36 states and the District of Columbia - AT&T's Mobility Orange unit, which encompasses CWA Districts 1, 2-13, 4, 7 and 9.

Pfizer announced that the United States FDA has approved IXIFI, a chimeric human-murine monoclonal antibody against tumor necrosis factor, as a biosimilar to Remicade for all eligible indications of the reference product. The FDA has approved IXIFI as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn's disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis.

Western Alliance Bancorporation announced that during the first quarter of 2018 Robert Sarver will transition from Chairman and CEO to Executive Chairman. In conjunction with Sarver's change in role, Ken Vecchione will be promoted to Chief Executive Officer, Dale Gibbons to Vice Chairman and Chief Financial Officer, and James Haught to President and Chief Operating Officer, all effective April 1, 2018.

Aqua America announced that President and CEO Christopher H. Franklin has been elected chairman of the board, effective Jan. 1, 2018. Franklin became CEO in July 2015 and has served on the board of directors since October 2015. He succeeds Nicholas DeBenedictis, former CEO, who will continue to serve on the board as chairman emeritus.